↓ Skip to main content

Cancer immunotherapies targeting the PD-1 signaling pathway

Overview of attention for article published in Journal of Biomedical Science, April 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#18 of 997)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
6 news outlets
blogs
1 blog
twitter
15 tweeters
patent
9 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
410 Dimensions

Readers on

mendeley
645 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cancer immunotherapies targeting the PD-1 signaling pathway
Published in
Journal of Biomedical Science, April 2017
DOI 10.1186/s12929-017-0329-9
Pubmed ID
Authors

Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo

Abstract

Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 645 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 <1%
Unknown 644 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 117 18%
Student > Ph. D. Student 83 13%
Student > Master 82 13%
Researcher 80 12%
Other 45 7%
Other 115 18%
Unknown 123 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 142 22%
Medicine and Dentistry 122 19%
Immunology and Microbiology 67 10%
Agricultural and Biological Sciences 53 8%
Pharmacology, Toxicology and Pharmaceutical Science 32 5%
Other 92 14%
Unknown 137 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 73. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2022.
All research outputs
#499,527
of 22,962,258 outputs
Outputs from Journal of Biomedical Science
#18
of 997 outputs
Outputs of similar age
#11,672
of 308,981 outputs
Outputs of similar age from Journal of Biomedical Science
#1
of 14 outputs
Altmetric has tracked 22,962,258 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 997 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.